更新于：2024-12-12
Betahistine Hydrochloride
盐酸倍他司汀
更新于：2024-12-12
概要
基本信息
原研机构- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1966-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C8H13ClN2 |
InChIKeyPIIWYFURBFSHKM-UHFFFAOYSA-N |
CAS号5579-84-0 |
关联
58
项与 盐酸倍他司汀 相关的临床试验盐酸倍他司汀片人体生物等效性研究
盐酸倍他司汀片（8mg）在中国成年健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、交叉生物等效性试验
盐酸倍他司汀片（8mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 盐酸倍他司汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸倍他司汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸倍他司汀 相关的专利（医药）
登录后查看更多信息
650
项与 盐酸倍他司汀 相关的文献（医药）2024-12-01SLEEP MEDICINE
Signal detection of drugs associated with obstructive and central sleep apnoea
Article
作者: Joyeux-Faure, M ; Hlavaty, A ; Khouri, C. ; Jambon-Barbara, C. ; Hlavaty, A. ; Pepin, J L ; Borel, J C ; Cracowski, J.L. ; Khouri, C ; Pepin, J.L. ; Revol, B ; Cracowski, J L ; Revol, B. ; Joyeux-Faure, M. ; Borel, J.C. ; Jambon-Barbara, C
We aim to discover new safety signals of drug-induced sleep apnoea (SA), a global health problem affecting approximately 1 billion people worldwide. We first conducted a series of sequence symmetry analyses (SSA) in a cohort composed from all patients who received a first SA diagnosis or treatment between 2006 and 2018 in the Echantillon Généraliste des Bénéficaires (EGB), a random sample of the French healthcare database. We used two primary outcomes to estimate the sequence ratio (SR) for all drug classes available in France: a sensitive one (diagnosis or treatment of SA) and a specific one (Positive Airway Pressure (PAP) therapy). We then performed disproportionality analyses using the "Bayesian neural network method" on all cases of sleep apnoea (MedDRA high level term) reported up to November 2023 in the World Health Organisation (WHO) pharmacovigilance database. Among the 728,167 individuals, 46,193 had an incident diagnosis or treatment for SA and 17,080 had started an incident treatment by PAP therapy. Fifty-eight drug classes had a significant SR, with 7 considered highly plausible: opium alkaloids and derivatives, benzodiazepine derivatives, other centrally acting agents, other anxiolytics, carbamic acid esters, quinine and derivatives and antivertigo preparations; with consistent signals found for the first 3 drug classes in the disproportionality analysis. In this signal detection study, we found that opioids, benzodiazepines (but not Z-drugs) and myorelaxing agents are associated with the onset or aggravation of SA. Moreover, a new safety signal for antivertigo preparations such as betahistine emerged and needs to be further explored.
2024-12-01Laryngoscope Investigative Otolaryngology
Effect of betahistine on pro‐inflammatory cytokine expression in autoimmune inner ear disease and Meniere's disease patients
Article
作者: Pathak, Shresh ; Yellin, Ilana ; Vambutas, Andrea
Abstract:
Objective:
Betahistine is a partial H1 receptor agonist and a potent H3 receptor antagonist commonly used for the treatment of MD and peripheral vertigo. The aim of this study was to investigate the impact of betahistine on the salt induced cytokine expression profiles of AIED and MD patients.
Methods:
Peripheral blood mononuclear cells (PBMCs) were obtained from 24 patients with autoimmune inner ear disease (AIED) or Meniere's disease (MD) during an acute exacerbation of hearing loss. These PBMCs were cultured with 80 mM NaCl or a combination of 80 mM NaCl and betahistine and IL‐1β and IL‐6 expression were measured by real time PCR and ELISA.
Results:
In most patients, IL‐1β expression in response to NaCl exceeded the unstimulated condition and this expression was abrogated by the addition of betahistine, which was statistically significant at p = .004. mRNA expression of IL‐1β was not reduced when samples were treated with both salt and betahistine compared to samples treated with salt alone, inferring the mechanism of betahistine‐mediated IL‐1β suppression is post‐translational. Similarly, IL‐6 cellular release was augmented with salt exposure and reduced with co‐culture of betahistine. Unlike IL‐1 however, betahistine appeared to reduce IL‐6 mRNA expression.
Conclusion:
We observe that betahistine abrogates salt‐induced IL‐1β expression, suggesting an additional treatment option for AIED and MD patients with inflammatory mediated disease.
Level of evidence:
Level 4.
2024-10-25MEDICINE
Trousseau syndrome with recurrent cerebral infarction as the first oneset in a gastrointestinal malignant tumor patient: A case report
Article
作者: Tian, Jing ; Wang, Rui ; Wang, Ye ; Yang, Yi ; Liu, Xiaoyun ; Zhang, Kun ; Feng, Yuyao ; Meng, Chaoyue
Rationale::
Trousseau syndrome (TS) is a thrombosis disorder characterized by a hypercoagulable state linked to underlying malignancies, resulting in various thrombotic events such as deep vein thrombosis, pulmonary embolism, and arterial thrombosis. This syndrome serves as a crucial indicator of malignancy and can often be the first sign of an underlying tumor. In this case, we report a case of gastrointestinal malignant tumor as the first onset, and analyzes its clinical characteristics to improve the clinicians’ understanding of this kind of disease.
Patient concerns::
A 69-year-old woman was admitted to the hospital 4 times in 1 month for cerebral infarction. The patient was admitted several times with a new cerebral infarction lesion and a high D-dimer level, a persistently positive fecal occult blood test, and a gastrointestinal tumor was later found.
Diagnosis::
The patient was diagnosed with TS, attributed to her underlying malignancy.
Interventions::
During hospitalization, the patients were treated with aspirin for antiplatelet, esomeprazole for protection of gastric mucosa, atorvastatin for lowering blood lipids, butylphthalein for improvement of collateral circulation, edaravone dextrocamphorol for scavenging oxygen free radicals, and betahistine hydrochloride tablets for preventing dizziness.
Outcomes::
The patient’s condition improved significantly after initial treatment, but died of the tumor a year after discharge.
Lessons::
Currently, TS has a complex and varied clinical presentation and is relatively difficult to diagnose, especially in patients with an unknown tumor history. Focus should be placed on patients with recurrent cerebral infarctions and increased D-dimer levels, and anticoagulation may be an effective treatment for patients with TS.
100 项与 盐酸倍他司汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉硬化 | 中国 | 1984-01-01 | |
| 脑血管疾病 | 中国 | 1984-01-01 | |
| 耳鸣 | 中国 | 1984-01-01 | |
| 眩晕 | 中国 | 1984-01-01 | |
| 梅尼埃病 | 美国 | - | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高胆固醇血症 | 临床2期 | 以色列 | 2007-05-01 | |
| 体重增加 | 临床2期 | 加拿大 | 2007-03-01 | |
| 体重增加 | 临床2期 | 以色列 | 2007-03-01 | |
| 肥胖 | 临床2期 | 美国 | 2007-01-01 | |
| 前庭疾病 | 临床申请 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 梅尼埃病 一线 | 15 | Betahistine alone (24 mg) | 膚簾遞窪願衊餘繭壓顧(廠顧鹹糧簾廠繭簾蓋選) = 鹹積觸遞選鏇衊獵淵簾 窪夢觸遞窪窪選餘壓築 (糧遞衊簾襯淵網簾壓衊, +/ ~ 0.47) | 积极 | 2023-01-01 | |
Betahistine alone (48 mg) | 膚簾遞窪願衊餘繭壓顧(廠顧鹹糧簾廠繭簾蓋選) = 膚願鏇夢鹹艱憲壓憲獵 窪夢觸遞窪窪選餘壓築 (糧遞衊簾襯淵網簾壓衊, +/ ~ 0.47) | ||||||
临床4期 | 124 | (Divaza) | 鏇繭積鑰範膚鬱鏇壓獵(範獵膚築顧鬱製獵膚襯) = 顧顧蓋遞鹽獵艱顧製淵 糧襯襯糧廠構觸繭遞積 (夢艱壓夢壓壓醖範簾淵, 鑰夢醖積遞製獵齋鹹糧 ~ 鬱壓壓積淵範衊鹽範淵) 更多 | - | 2021-08-26 | ||
Placebo (Placebo) | 鏇繭積鑰範膚鬱鏇壓獵(範獵膚築顧鬱製獵膚襯) = 蓋顧襯製簾齋遞憲鹹範 糧襯襯糧廠構觸繭遞積 (夢艱壓夢壓壓醖範簾淵, 築鹽醖願鹹積襯糧衊膚 ~ 夢壓糧憲膚製齋觸鏇窪) 更多 | ||||||
临床2期 | 48 | (Betahistine) | 獵窪觸蓋衊醖醖艱窪鏇(窪顧鏇繭繭憲壓觸醖醖) = 襯衊膚鑰築鬱齋齋鬱願 襯壓壓廠淵艱製齋淵鏇 (築製醖壓選觸製衊鏇襯, 餘膚衊蓋製築齋衊餘壓 ~ 衊製顧鹽餘蓋糧構鹹襯) 更多 | - | 2019-01-25 | ||
placebo (Placebo) | 獵窪觸蓋衊醖醖艱窪鏇(窪顧鏇繭繭憲壓觸醖醖) = 壓艱積衊鏇廠淵獵製蓋 襯壓壓廠淵艱製齋淵鏇 (築製醖壓選觸製衊鏇襯, 鹽廠選憲網艱齋願築廠 ~ 積廠遞齋艱膚鑰廠衊鹹) 更多 | ||||||
N/A | - | Betahistine dihydrochloride 48 mg | 鹹築鏇築襯壓糧鑰鹹壓(獵廠鹹簾網襯願範觸窪) = 遞網鹽鏇淵積繭範築網 齋憲淵觸餘壓製壓積遞 (積窪鑰觸餘餘範餘觸觸 ) 更多 | 积极 | 2003-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用